Xerostomia (grade >= 2, 0-3 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol led to lower xerostomia (grade >= 2, 0-3 scale) compared with placebo; GRADE not reported.
2 findings from 1 review
Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol showed no clear difference in salivary flow rate (stimulated, ml/min) compared with placebo; GRADE not reported.
1 finding from 1 review
Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether amifostine changes overall survival compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol led to higher salivary flow rate (unstimulated, ml/min) compared with placebo; GRADE not reported.
1 finding from 1 review
Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Survival (locoregional control) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Dysphagia · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Palifermin showed no clear difference in dysphagia compared with placebo; GRADE not reported.
1 finding from 1 review
RR 1.32 [0.55, 3.13]
3 studies
GRADE not reported
Locoregional control · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in locoregional tumour control compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Disability of oral intake · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc showed no clear difference in disability of oral intake compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Nausea · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Antimicrobial lozenge led to higher nausea (adverse effect) compared with placebo; GRADE not reported.
1 finding from 1 review
Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects (other reported events) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
No evidence of a difference for any other adverse event (nausea, vomiting, chilling, headache, lacrimation, dysphasia, weakness, nervousness, rhinitis, blurred vision, urinary frequency, dizziness, palpitation, skin…
Studies not reported
GRADE not reported
Nausea · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine 200 mg/m2 three times weekly showed no clear difference in nausea (adverse effect) compared with amifostine 200 mg/m2 five times weekly; GRADE not reported.
1 finding from 1 review
Xerostomia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine 200 mg/m2 three times weekly showed no clear difference in xerostomia (grade >= 2, 0-4 scale) compared with amifostine 200 mg/m2 five times weekly; GRADE not reported.
1 finding from 1 review
Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Mouth and throat soreness (OMWQ-HN, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Palifermin showed no clear difference in mouth and throat soreness (OMWQ-HN, 0-4 scale) compared with placebo; GRADE not reported.
1 finding from 1 review
MD -0.12 [-0.27, 0.02]
2 studies
GRADE not reported